Indication
Polypoidal Choroidal Vasculopathy
5 clinical trials
4 products
Product
ZimuraProduct
EyleaClinical trial
A Phase 2A Open-Label Trial to Assess the Safety of ZIMURA™ (Anti-C5) in Combination With EYLEA® in Treatment Experienced Subjects With Idiopathic Polypoidal Choroidal VasculopathyStatus: Withdrawn, Estimated PCD: 2019-12-01
Clinical trial
A Phase 2a Study to Establish the Safety and Tolerability of Zimura® (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)Status: Completed, Estimated PCD: 2015-10-01
Product
AfliberceptClinical trial
A Double-Masked, Multi-center, Active Controlled Safety and Efficacy Study of Adjunct Episcleral Brachytherapy for Polypoid Choroidal VasculopathyStatus: Not yet recruiting, Estimated PCD: 2026-09-01
Clinical trial
Tolerating Subretinal Fluid in Type 1 Macular Neovascularization and Polypoidal Choroidal Vasculopathy Treated Using AfliberceptStatus: Completed, Estimated PCD: 2023-05-31
Product
Intravitreal afliberceptClinical trial
A Multi-center Randomized Clinical Trial Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT for the Treatment of Polypoidal Choroidal VasculopathyStatus: Active (not recruiting), Estimated PCD: 2024-07-31